Premature Ejaculation Cures

When you start researching the subject of premature ejaculation on the web, you find everything from free articles written by experts, to low quality, cheezy crap thrown together by sales affiliates promoting everything from self-help cures to unnatural pills and awkward creams, sprays, and gels. Personally, I always prefer to approach health issues from an natural, internal perspective, with the goal of finding a real cure that addresses the cause of the problem, not just covering up the symptom.

Externally applied substances, or strange sexual aids,and devices, simply do not appeal to me as a real solution to the problem of premature ejaculation. Those seem more like superficial crutches, and in my opinion, they are temporary at best.

So, lets talk about a program that is specifically designed to work at the core level of the problem, to restore optimal function of the body – naturally, and without relying on crutches or “parlor tricks”.

Ejaculation Trainer is the best selling, highest quality training program available on the market for curing premature ejaculation. It was developed by professional sex therapist, Matt Wutske. The interesting thing about Matt is that this guy worked as a counselor for men on sexual issues, at the same point in his life that he was actually experiencing premature ejaculation as a problem in his own sex life. Kind of ironic, since his profession was that of helping other guys overcome their sexual dysfunction.

...Try Ejaculation Trainer...She'll Thank You Later

This just goes to show that so much of “conventional wisdom” and commonly accepted practices in the western medical approach to this problem simply don’t work. This man had advanced education and training as a sex therapist, and yet was unable at that time to make that knowledge work for him.

Ultimately, he became highly motivated to conquer his problem, not only for the satisfaction of having a healthy sex life, but to rid himself of the feeling of being a hypocrite in his professional life. This experience led him on a path to curing his own premature ejaculation, and that experience turned out to form the blueprint that has helped so many guys overcome the problem of premature ejaculation.

One great thing about Ejaculation Trainer is that it is not just a re-hash of all the same old “tips and tricks” for lasting longer that you hear all over the place from conventional wisdom to articles in men’s magazines online and off. Things like “stop and go”, or “the squeeze”, “PC exercises”, and the classic one that I heard in junior high for the first time: “Dude – just think about dead puppies (i.e. insert favorite stomach wrenching visual) and you’ll be fine…”

Okay, sure, some of those “tips” may be valid, and they may work occasionally or at least play a role in overall self-control while in bed. But, people have been trying to rely on that stuff for decades, and many men (somewhere between 40% and 75% depending on whose statistics you reference) are suffering from premature ejaculation. If those “free tips” hailing from “conventional wisdom” were really so effective, would so many of us still have this problem? Doubtful.

60-Day Money Back Guarantee

Ejaculation Supremacy is one of the newest downloadable training programs on the market for curing premature ejaculation. I’ve recently acquired a copy of it and went through it chapter by chapter, for the purpose of providing an unbiased review for my blog readers.

Ejaculation Supremacy was written by Chris Bailey. Chris claims to be at once a “regular Joe” and an “expert on premature ejaculation.” He describes his credentials as deriving from 9 years worth of experimentation with sexual techniques spanning sexual relations with more than 50 women (go Chris!) I could only guess he would be an expert after seeing that much action. Apparently, Chris also has experience counseling other men in overcoming premature ejaculation.

Ejaculation Supremacy covers a very complete range of approaches to premature ejaculation, from physical and mental techniques to topical treatments, erectile dysfunction medication, and the use of alcohol as a strategy to combatting PE. Although I don’t particularly subscribe to topical or internal pharmaceutical medicines, or alcohol, in dealing with premature ejaculation, I do like the idea that Ejaculation Supremacy acts as a kind of reference guide that makes an attempt to cover the subject from multiple perspectives, and provides a “something for everyone” approach to PE. Here is a quick screen shot of the Ejaculation Supremacy Table of Contents:

Review of Ejaculation Supremacy Table of Contents

As you can see from the table of contents, Ejaculation Supremacy packs a fairly large volume of information on a wide range of issues relevant to premature ejaculation cures.

One notable characteristic of this book that makes it quite useful is Chris’s organizational structure of each chapter, especially those which cover a particular method or cure. In essence, he identifies the subject, describes what it is and how it works, and then includes a “hands on” module that explains in exact detail how to implement the particular technique or cure immediately. He concludes each one of these with a “Verdicts” section that prompts the reader to draw their own conclusions about how well the technique worked for them. In essence, he is inviting the reader to try every and all of the possible solutions, according to their own tastes and preferences.

I found the section on hypnosis intriguing, because this is not a technique that I have much experience with, but it seem intuitively to be worth exploring. He specifically gets into self-hypnosis, which appeals to me much as being more useful, and less embarassing, than working with a hypnotherapist for the purposes of overcoming PE.

Also, Chris rightly teaches his readers to choose a mind set towards sex that involves putting the pleasure of your partner over your own, as a practical matter in controlling premature ejaculati0n, and also to help his readers understand that the experience of sexual union goes beyond physical pleasure.

Overall, Chris’s resource is very complete, and offers a practical step-by-step approach to implementing a wide variety of techniques for curing premature ejaculation. Although several of his methods do not resonate with me as options I personally would pursue, such as the use of topical treatments or alcohol, I understand that they will appeal to a percentage of people as perfectly valid and easy to implement options. And 0n the other hand, I find a fair majority of his techniques in total agreement with my own overall beliefs and approaches.

I would make a final note about Chris’s generous bonus package. Besides the main text of Ejaculation Supremacy, you also receive 5 bonus manuls covering everything from enlarging your penis size naturally, to the secrets of giving your woman ecstatic orgasms. In fact, here is a complete list of the bonuses you receive with this book, which also includes a standard 60 day money-back guarantee:

Special Limited Access Bonuses

Free Bonus #1 – Breaking The Forward Feedback Loop – in this report, you’ll discover why the breaking the psychological barrier of forward feedback loop is critical to overcoming PE. I’ll show you exactly how it works and give you practical steps to defeat it.

Free Bonus #2 – Develop Your Inner Self – in this report, I’ll reveal to you the often neglected “out of bedroom” factors that simply cannot be ignored if you want to defeat your PE. You’ll be amazed when I help you to make your own revelation and use it to become a stud in the bedroom.

Free Bonus #3 – How To Give Your Woman Screaming Orgasms – this is the perfect companion report to Ejaculation Supremacy! Defeating PE is the main hurdle in becoming a master lover. But what if you make your woman beg you to bring her to yet another shuddering orgasm like no other man can?

Free Bonus #4 – Penis Enlargement Secrets – You may have heard of “penis enlargement” and think it is purely a scam. In this report, I’ll prove to you that it is not, and I’ll also show you the only 2 ways that a man can achieve an extra couple of inches.

Free Bonus #5 – Tapping For Premature Ejaculation – in this report, I’ll share with you the amazing technique of “tapping” that therapists the world over are using to cure people. I’ll share with you the specific techniques to cure PE. There is simply nowhere else on the internet that you can find these!

Chris Bailey’s Ejaculation Supremacy is a highly complete, authoritive survey of how to cure premature ejaculation. It provides a great deal of actionable content, along with a very healthy offering of bonus material. My suggestion to you is to look over the Table of Contents above. If you find that you are interested in or drawn to a fair number of the topics covered in the book then you will likely be very happy with your purchase. If for any reason you are not, the 60 day money back guarantee eliminates all risk to you. You can, for any or no reason at all, request your money back and will receive it, no questions asked. You even get to keep all the material (including bonuses) so there really is no risk. Click the image below and check out the order page for more information at Ejaculation Supremacy:

Ejaculation Supremacy

J Sex Med. 2012 Jan 16;
Asimakopoulos AD, Miano R, Agrò EF, Vespasiani G, Spera E

Introduction.  Premature ejaculation (PE) is a highly prevalent and complex syndrome that remains poorly defined and inadequately characterized. Pharmacotherapy represents the current basis of lifelong PE treatment. Aim.  The goal of this study was to assess the role of phosphodiesterase type 5 inhibitors (PDE5-Is) in the treatment of patients with PE without associated erectile dysfunction (ED). Main Outcome Measure.  The posttreatment intravaginal ejaculatory latency time was used as the primary end point of efficacy. Methods.  A systematic review of the literature was performed by electronically searching the MedLine database for peer-reviewed articles regarding the mechanism of action and the clinical trials of PDE5 in the management of PE. A meta-analysis of these clinical studies was performed to pool the efficacy. Results.  Twenty-nine articles that examined the supposed mechanisms of action and 14 articles that reported data from clinical studies were reviewed. The PDE5 may exert their influence by increasing the levels of nitric oxide both centrally (reducing sympathetic drive) and peripherally (leading to smooth-muscle dilatation of the seminal tract). These drugs may also induce peripheral analgesia to prolong the duration of the erection, increase confidence, improve the perception of ejaculatory control and overall sexual satisfaction, and decrease the postorgasmic refractory time for achieving a second erection after ejaculation. Concerning the efficacy, the meta-analysis shows an overall positive effect for the use of PDE5 as monotherapy or as components of a combination regimen in the treatment of PE. The major limitations of the published literature included poor study design, the absence of solid methodology, which was characterized by the lack of a unique PE definition, and the lack of appropriate endpoints for outcome evaluation of a placebo control arm and of Institutional Review Board approval. Conclusion.  There is inadequate, partial basic, and clinical evidence to support the use of PDE5 for the treatment of PE. Asimakopoulos AD, Miano R, Agrò EF, Vespasiani G, and Spera E. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? A systematic review and meta-analysis. J Sex Med **;**:**-**.

Read Full Article

J Sex Med. 2012 Jan 16;
Asimakopoulos AD, Miano R, Agrò EF, Vespasiani G, Spera E

Introduction.  Premature ejaculation (PE) is a highly prevalent and complex syndrome that remains poorly defined and inadequately characterized. Pharmacotherapy represents the current basis of lifelong PE treatment. Aim.  The goal of this study was to assess the role of phosphodiesterase type 5 inhibitors (PDE5-Is) in the treatment of patients with PE without associated erectile dysfunction (ED). Main Outcome Measure.  The posttreatment intravaginal ejaculatory latency time was used as the primary end point of efficacy. Methods.  A systematic review of the literature was performed by electronically searching the MedLine database for peer-reviewed articles regarding the mechanism of action and the clinical trials of PDE5 in the management of PE. A meta-analysis of these clinical studies was performed to pool the efficacy. Results.  Twenty-nine articles that examined the supposed mechanisms of action and 14 articles that reported data from clinical studies were reviewed. The PDE5 may exert their influence by increasing the levels of nitric oxide both centrally (reducing sympathetic drive) and peripherally (leading to smooth-muscle dilatation of the seminal tract). These drugs may also induce peripheral analgesia to prolong the duration of the erection, increase confidence, improve the perception of ejaculatory control and overall sexual satisfaction, and decrease the postorgasmic refractory time for achieving a second erection after ejaculation. Concerning the efficacy, the meta-analysis shows an overall positive effect for the use of PDE5 as monotherapy or as components of a combination regimen in the treatment of PE. The major limitations of the published literature included poor study design, the absence of solid methodology, which was characterized by the lack of a unique PE definition, and the lack of appropriate endpoints for outcome evaluation of a placebo control arm and of Institutional Review Board approval. Conclusion.  There is inadequate, partial basic, and clinical evidence to support the use of PDE5 for the treatment of PE. Asimakopoulos AD, Miano R, Agrò EF, Vespasiani G, and Spera E. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? A systematic review and meta-analysis. J Sex Med **;**:**-**.

Read Full Article

J Sex Med. 2012 Jan 16;
Asimakopoulos AD, Miano R, Agrò EF, Vespasiani G, Spera E

Introduction.  Premature ejaculation (PE) is a highly prevalent and complex syndrome that remains poorly defined and inadequately characterized. Pharmacotherapy represents the current basis of lifelong PE treatment. Aim.  The goal of this study was to assess the role of phosphodiesterase type 5 inhibitors (PDE5-Is) in the treatment of patients with PE without associated erectile dysfunction (ED). Main Outcome Measure.  The posttreatment intravaginal ejaculatory latency time was used as the primary end point of efficacy. Methods.  A systematic review of the literature was performed by electronically searching the MedLine database for peer-reviewed articles regarding the mechanism of action and the clinical trials of PDE5 in the management of PE. A meta-analysis of these clinical studies was performed to pool the efficacy. Results.  Twenty-nine articles that examined the supposed mechanisms of action and 14 articles that reported data from clinical studies were reviewed. The PDE5 may exert their influence by increasing the levels of nitric oxide both centrally (reducing sympathetic drive) and peripherally (leading to smooth-muscle dilatation of the seminal tract). These drugs may also induce peripheral analgesia to prolong the duration of the erection, increase confidence, improve the perception of ejaculatory control and overall sexual satisfaction, and decrease the postorgasmic refractory time for achieving a second erection after ejaculation. Concerning the efficacy, the meta-analysis shows an overall positive effect for the use of PDE5 as monotherapy or as components of a combination regimen in the treatment of PE. The major limitations of the published literature included poor study design, the absence of solid methodology, which was characterized by the lack of a unique PE definition, and the lack of appropriate endpoints for outcome evaluation of a placebo control arm and of Institutional Review Board approval. Conclusion.  There is inadequate, partial basic, and clinical evidence to support the use of PDE5 for the treatment of PE. Asimakopoulos AD, Miano R, Agrò EF, Vespasiani G, and Spera E. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? A systematic review and meta-analysis. J Sex Med **;**:**-**.

Read Full Article

J Sex Med. 2012 Jan 3;
Shindel AW, Vittinghoff E, Breyer BN

Introduction.  Quantitative research into sexual function and dysfunction in men who have sex with men (MSM) has been sparse due in large part to a lack of validated, quantitative instruments for the assessment of sexuality in this population. Aim.  To assess prevalence and associations of erectile problems and premature ejaculation in MSM. Methods.  MSM were invited to complete an online survey of sexual function. Ethnodemographic, sexuality, and health-related factors were assessed. Main Outcome Measure.  Participants completed a version of the International Index of Erectile Function modified for use in MSM (IIEF-MSM) and the Premature Ejaculation Diagnostic Tool (PEDT). Total score on the erectile function (EF) domain of the IIEF-EF (IIEF-MSM-EF) was used to stratify erectile dysfunction (ED) severity (25-30 = no ED, 16-24 mild or mild moderate ED, 11-15 moderate ED, and ≤10 severe ED). PEDT scores were used to stratify risk of premature ejaculation (PE, diagnosed as PEDT score ≥9). Results.  Nearly 80% of the study cohort of 2,640 men resided in North America. The prevalence of ED was higher in older men whereas the prevalence of PE was relatively constant across age groups. Multivariate logistic regression revealed that increasing age, HIV seropositivity, prior use of erectogenic therapy, lower urinary tract symptoms (LUTS), and lack of a stable sexual partner were associated with greater odds of ED. A separate multivariate analysis revealed that younger age, LUTS, and lower number of lifetime sexual partners were associated with greater odds of PE. Conclusions.  Risk factors for sexual problems in MSM are similar to what has been observed in quantitative studies of non-MSM males. Urinary symptoms are associated with poorer sexual function in MSM. Shindel AW, Vittinghoff E, and Breyer BN. Erectile dysfunction and premature ejaculation in men who have sex with men. J Sex Med **;**:**-**.

Read Full Article

J Sex Med. 2012 Jan 3;
Shindel AW, Vittinghoff E, Breyer BN

Introduction.  Quantitative research into sexual function and dysfunction in men who have sex with men (MSM) has been sparse due in large part to a lack of validated, quantitative instruments for the assessment of sexuality in this population. Aim.  To assess prevalence and associations of erectile problems and premature ejaculation in MSM. Methods.  MSM were invited to complete an online survey of sexual function. Ethnodemographic, sexuality, and health-related factors were assessed. Main Outcome Measure.  Participants completed a version of the International Index of Erectile Function modified for use in MSM (IIEF-MSM) and the Premature Ejaculation Diagnostic Tool (PEDT). Total score on the erectile function (EF) domain of the IIEF-EF (IIEF-MSM-EF) was used to stratify erectile dysfunction (ED) severity (25-30 = no ED, 16-24 mild or mild moderate ED, 11-15 moderate ED, and ≤10 severe ED). PEDT scores were used to stratify risk of premature ejaculation (PE, diagnosed as PEDT score ≥9). Results.  Nearly 80% of the study cohort of 2,640 men resided in North America. The prevalence of ED was higher in older men whereas the prevalence of PE was relatively constant across age groups. Multivariate logistic regression revealed that increasing age, HIV seropositivity, prior use of erectogenic therapy, lower urinary tract symptoms (LUTS), and lack of a stable sexual partner were associated with greater odds of ED. A separate multivariate analysis revealed that younger age, LUTS, and lower number of lifetime sexual partners were associated with greater odds of PE. Conclusions.  Risk factors for sexual problems in MSM are similar to what has been observed in quantitative studies of non-MSM males. Urinary symptoms are associated with poorer sexual function in MSM. Shindel AW, Vittinghoff E, and Breyer BN. Erectile dysfunction and premature ejaculation in men who have sex with men. J Sex Med **;**:**-**.

Read Full Article

Neuropharmacology. 2011 Dec 14;
Jeong I, Kim SW, Yoon SH, Hahn SJ

Dapoxetine, a short-acting selective serotonin reuptake inhibitor, is widely prescribed for the treatment of patients with premature ejaculation. The effects of dapoxetine were examined on cloned Kv4.3 channels stably expressed in Chinese hamster ovary cells using the whole-cell patch-clamp technique. Dapoxetine not only reduced the peak amplitude of Kv4.3 currents but also accelerated the decay rate of current inactivation in a concentration-dependent manner. Thus, the concentration-dependent reduction in Kv4.3 was measured from the integral of the current during the depolarizing pulse. Dapoxetine decreased the integral of the Kv4.3 currents over the duration of a depolarizing pulse with an IC(50) of 5.3μM. Analysis of the time dependence of the block gave estimates of an association rate constant (k(+1)) of 3.9μM(-1)s(-1) and a dissociation rate constant (k(-1)) of 25.6s(-1). The K(D) (k(-1)/k(+1)) was 6.5μM, similar to the IC(50) value calculated from the concentration-response curve. The block of Kv4.3 by dapoxetine was highly voltage-dependent at a membrane potential coinciding with the activation of the channels. The additional block by dapoxetine displayed a shallow voltage dependence (δ=0.21) in the full activation voltage range. The steady-state inactivation curves were shifted in the hyperpolarizing direction in the presence of dapoxetine. Dapoxetine also caused a substantial acceleration in closed-state inactivation. Dapoxetine produced a significant use-dependent block, which was accompanied by a delayed recovery from inactivation of Kv4.3 currents. These results indicated that dapoxetine potently blocks Kv4.3 currents by both preferentially binding to the open state of the channels and accelerating the closed-state inactivation. These data could provide insight into the mechanism underlying some of the therapeutic actions of this drug.

Read Full Article

J Sex Med. 2011 Dec 21;
Luján S, García-Fadrique G, Morales G, Morera J, Broseta E, Jiménez-Cruz JF

Introduction.  The management of premature ejaculation (PE) among urology residents (URs) in the era of standard definition and new treatments is unknown. Aim.  To determine how future urologists currently address PE and to review their adherence to guidelines. Methods.  A specifically designed survey on the preferred approaches to the treatment of PE was given to residents during the Eighth European Urology Education Programme. The results were tabled, and descriptive statistics were used to analyze differences in practice patterns. Main Outcomes Measures.  The responses are compared with clinical guidelines and recommendations. Results.  A total of 360 URs attended the recommendation course, and 140 answered the survey (response rate: 38.8%). Seventeen (12.1%) of the respondents considered PE to be a very common sexual dysfunction, 62 (44.3%) considered PE to be frequent, 33 (23.6%) considered this condition uncommon, and 28 (20%) did not consider PE to be a dysfunction. Regarding incidents, 67 residents (47.9%) treated one patient per week. To assess PE, 132 (94.3%) used sexual history, 37 (26.4%) used physical examination, 38 (27.1%) used questionnaires, and 4 (2.9%) used laboratory testing. The preferred initial management strategy for PE was psychological/behavioral therapy for 65 (46.4%) residents. Topical anesthetic, andrological referral, and prescription of selective serotonin reuptake inhibitors (SSRIs) on demand were favored by 34 (24.3%), 19 (13.6%), and 8 (12.9%) of the respondents, respectively. Other options were psychiatric referral, which was preferred by two (1.4%) respondents, and prescription of daily SSRIs, which was preferred by two (1.4%) respondents. The preferred secondary treatment for patients who did not improve initially was prescription of SSRIs for on demand, which was 46 (32.9%) respondents. In cases where patients had concomitant erectile dysfunction (ED), 16 (11.4%) URs treated only the ED and 60 (42.9%) treated both conditions. Conclusions.  The majority of URs follow the established guidelines for diagnosis of PE, but not for treatment. The URs have an insufficient medical education in sexual medicine. Luján S, García-Fadrique G, Morales G, Morera J, Broseta E, and Jiménez-Cruz JF. Are urology residents ready to treat premature ejaculation after their training? J Sex Med **;**:**-**.

Read Full Article

J Sex Med. 2011 Dec 21;
Luján S, García-Fadrique G, Morales G, Morera J, Broseta E, Jiménez-Cruz JF

Introduction.  The management of premature ejaculation (PE) among urology residents (URs) in the era of standard definition and new treatments is unknown. Aim.  To determine how future urologists currently address PE and to review their adherence to guidelines. Methods.  A specifically designed survey on the preferred approaches to the treatment of PE was given to residents during the Eighth European Urology Education Programme. The results were tabled, and descriptive statistics were used to analyze differences in practice patterns. Main Outcomes Measures.  The responses are compared with clinical guidelines and recommendations. Results.  A total of 360 URs attended the recommendation course, and 140 answered the survey (response rate: 38.8%). Seventeen (12.1%) of the respondents considered PE to be a very common sexual dysfunction, 62 (44.3%) considered PE to be frequent, 33 (23.6%) considered this condition uncommon, and 28 (20%) did not consider PE to be a dysfunction. Regarding incidents, 67 residents (47.9%) treated one patient per week. To assess PE, 132 (94.3%) used sexual history, 37 (26.4%) used physical examination, 38 (27.1%) used questionnaires, and 4 (2.9%) used laboratory testing. The preferred initial management strategy for PE was psychological/behavioral therapy for 65 (46.4%) residents. Topical anesthetic, andrological referral, and prescription of selective serotonin reuptake inhibitors (SSRIs) on demand were favored by 34 (24.3%), 19 (13.6%), and 8 (12.9%) of the respondents, respectively. Other options were psychiatric referral, which was preferred by two (1.4%) respondents, and prescription of daily SSRIs, which was preferred by two (1.4%) respondents. The preferred secondary treatment for patients who did not improve initially was prescription of SSRIs for on demand, which was 46 (32.9%) respondents. In cases where patients had concomitant erectile dysfunction (ED), 16 (11.4%) URs treated only the ED and 60 (42.9%) treated both conditions. Conclusions.  The majority of URs follow the established guidelines for diagnosis of PE, but not for treatment. The URs have an insufficient medical education in sexual medicine. Luján S, García-Fadrique G, Morales G, Morera J, Broseta E, and Jiménez-Cruz JF. Are urology residents ready to treat premature ejaculation after their training? J Sex Med **;**:**-**.

Read Full Article

Int J Impot Res. 2011 Dec 8;
Aversa A, Francomano D, Bruzziches R, Natali M, Guerra A, Latini M, Donini LM, Lenzi A

There are no interventional studies on the impact of sexual distress (SD) in men with obesity. We investigated the effects of vardenafil (VAR) on SD in middle-aged (mean age 49±8), healthy, obese men in the absence of premature ejaculation, ED or hypogonadism. After a 4-week run-in period, 20 men with high body mass index (BMI=40±8) and SD at the Sexual Distress Esteem Questionnaire-Male (mean score 65±20 AU) were randomized to receive either VAR 10 mg on demand (N=10) or matched-placebo (PLB, N=10). Primary endpoints were variations from baseline in the intravaginal ejaculatory latency time (IELT) measured by the stopwatch technique; secondary endpoints were variations from baseline in Self-Esteem and Relationship (SEAR) and Male Sexual Health Questionnaire-Ejaculatory domain (MSHQ-EjD) scores. VAR significantly improved IELT (P<0.0001), as well as SEAR (P<0.001) and MSHQ-EjD (P<0.005) scores, wheraes no changes were observed after PLB. Interestingly, an inverse relationship between BMI and IELT was found in all the men studied (r(2)=0.37, P<0.001). SD in healthy obese men seems to be correlated mainly with inadequate ejaculatory control, especially in men with higher BMI. Our preliminary results suggest that treatment with VAR may improve ejaculatory control, thus ameliorating self-esteem and sexual performance in men with obesity.International Journal of Impotence Research advance online publication, 8 December 2011; doi:10.1038/ijir.2011.52.

Read Full Article

J Sex Med. 2011 Dec 6;
Shaeer O, Shaeer K, Shaeer E

Introduction.  The exact prevalence of female sexual dysfunction (FSD) in the Middle East is exceptionally difficult to measure in light of its sensitive nature and the conservative tinge of the population. Aim.  The Global Online Sexuality Survey-Arabic-Females (GOSS-AR-F) is a community-based study of female sexuality in the Middle East through an online survey. Main Outcome Measures.  Prevalence of risk for female sexual dysfunction (rFSD) in the reproductive age group and its vulnerability to various risk factors. Methods.  GOSS-AR-F was offered via online advertising. The survey is comprised of the Female Sexual Function Index (FSFI) questionnaire among other questions. Results.  Out of 2,920 participants, 344 participants completed all survey questions. Average total FSFI score was 23 ± 6.5, with 59.1% of participants suffering rFSD. Age adjusted prevalence of rFSD was 59.5%, standardized to World Health Organization World Standard Population. There was a statistically significant higher prevalence of rFSD among cases with subjectively reported depression and male partner-related shortcomings such as erectile dysfunction and premature ejaculation as reported by the female participant, in addition to dissatisfaction with partner’s penile size, insufficient foreplay, and practice of masturbation. This was not the case with advancing age, diabetes mellitus, hypertension, smoking, ongoing pregnancy, mode of previous child delivery, infertility, menstrual irregularities, dysmenorrhea, interpersonal distress, subjectively reported hirsutism, and female genital cutting. Participants were found to require longer duration of coitus and better ejaculatory control but not necessarily a higher coital frequency. Conclusion.  Female sexual function in the reproductive age appears to be adversely affected by psychological factors and shortcomings in male sexual function more than anything. These findings point to the possibility that many cases of FSD can be managed with the focus on male partner’s ailments and attitudes that are relatively easier to manage. Shae er O, Shaeer K, and Shaeer E. The Global Online Sexuality Survey (GOSS): Female sexual dysfunction among Internet users in the reproductive age group in the Middle East. J Sex Med **;**:**-**.

Read Full Article